Recombinant human granulocyte-stimulating factor injection

After intravenous or subcutaneous injection, this product is mainly distributed in the kidney, bone marrow and plasma, degraded by amino acid metabolism, and mainly excreted in urine. When injected subcutaneously, the half-life is 3.5 hours and the clearance rate is 0.5-0.7 ml/min/kg.

recombinant human granulocyte colony stimulating factor

Colorless transparent liquid.

1. Neutropenia caused by cancer chemotherapy and other reasons; cancer patients use bone marrow suppressive chemotherapy drugs, especially after strong bone marrow deprivation chemotherapy drugs, injection of this product can help prevent the occurrence of neutropenia, reduce the degree of neutropenia, shorten the duration of agranulocytosis, accelerate the recovery of granulocyte count, and thus reduce the risk of concurrent infection and fever. 2. Promote the increase of neutrophil count after bone marrow transplantation. 3. Neutropenia caused by myelodysplastic syndrome, neutropenia caused by aplastic anemia, congenital and idiopathic neutropenia, myelodysplastic syndrome with neutropenia, and cyclical neutropenia.

1. For neutropenia caused by chemotherapy of tumors. For adult patients whose neutrophil count drops below 1000/mm3 (white blood cell count 2000/mm3) after chemotherapy, 2-5g/kg should be administered subcutaneously or intravenously once a day after chemotherapy. For children whose neutrophil count drops below 500/mm3 (white blood cell count 1000/mm3) after chemotherapy, 2-5g/kg should be administered subcutaneously or intravenously once a day after chemotherapy. When the neutrophil count rises above 5000/mm3 (white blood cell count 10000/mm3), stop the administration. 2. Acute leukemia Neutropenia caused by chemotherapy: Leukemia patients with white blood cell count less than 1000/mm3 after chemotherapy, when the myeloblasts in the bone marrow are significantly reduced and no myeloblasts are found in the peripheral blood. Adult patients should be given 2-5 g/kg once a day by subcutaneous or intravenous injection; children should be given 2 g/kg once a day by subcutaneous or intravenous injection. Stop the medication when the neutrophil count rises above 5000/mm3 (white blood cell count 10000/mm3). 3 Myelodysplastic syndrome with neutropenia: Adult patients with neutrophil count less than 1000/mm3 should be given 2-5 g/kg Administer once a day subcutaneously or intravenously. Stop administration when the neutrophil count rises above 5000/mm3. 4. For neutropenia caused by aplastic anemia, when the neutrophil count is less than 1000/mm3, in adult patients, 2-5 g/kg is administered subcutaneously or intravenously once a day. When the neutrophil count rises above 5000/mm3, reduce the dose or stop administration as appropriate. 5. For cyclic neutropenia, autoimmune neutropenia, and chronic neutropenia, when the neutrophil count is less than 1000/mm3, in adult patients, 1 g/kg is administered subcutaneously or intravenously once a day. When the neutrophil count of children is less than 1000/mm3, 1g/kg is administered subcutaneously or intravenously once a day. When the neutrophil count rises to above 5000/mm3, the dose can be reduced or stopped as appropriate. 6. Used to promote the increase of neutrophils in bone marrow transplant patients. Adults should start taking the drug on the second to fifth day of bone marrow transplantation. 2-5g/kg is administered subcutaneously or intravenously once a day. Children should start taking the drug on the second to fifth day of bone marrow transplantation. 2g/kg is administered subcutaneously or intravenously once a day. When the neutrophil count rises to above 5000/mm3 (white blood cell count 10000/mm3), the drug should be stopped.

1. Musculoskeletal system: sometimes there will be muscle aches, bone pain, back pain, and chest pain. 2. Digestive system: sometimes there will be loss of appetite or elevated liver alanine aminotransferase and aspartate aminotransferase. 3. Others: some people will have fever, headache, fatigue, and rash. ALPLDH elevation. 4. Very few people will experience shock, interstitial pneumonia, and adult respiratory distress syndrome. Increased immature cells.

1. Patients who are allergic to granulocyte colony-stimulating factor and other preparations expressed by Escherichia coli are contraindicated. 2. Patients with severe liver, kidney, heart and lung dysfunction are contraindicated. 3. Myeloid leukemia patients whose immature granulocytes in the bone marrow have not been significantly reduced or whose immature granulocytes have been detected in the peripheral blood.

Precautions for children: Use with caution in children and give appropriate monitoring; since the safety of the drug for newborns and infants has not been determined, it is recommended not to use the drug. No long-term toxic effects were found in patients aged 4 months to 17 years who took the drug daily, and their growth, development, sexual characteristics and endocrine system were not changed. Precautions for pregnancy and lactation: Safety during pregnancy has not been established. When it is proven that the potential benefits of the drug for pregnant women outweigh the potential risks to the fetus, it should be used. Lactating women should stop breastfeeding before taking the drug. Precautions for the elderly: The physiological function of elderly patients is relatively low, so it is necessary to observe the patient's condition, pay attention to the dosage and interval, and administer the drug with caution. Its safety and effectiveness have not yet been established.

It is not yet completely clear whether drugs that promote the release of white blood cells (such as lithium) should be used with caution

Store at 2-8℃ away from light.

100 micrograms/vial

24 months

Xiamen Amoytop Biotech Co., Ltd.

• Founded in:

  1996-08-07

• Address:

  No. 330, Wengjiao Road, Xinyang Industrial Zone, Haicang, Xiamen

• Tax NO.:

  913502002600603688

• Registered Funds:

  406.8 million yuan

• Website:

  Log in to view

• Email:

  Log in to view